OIS Index Follows Biotech Stocks Lower in October

OIS Index Follows Biotech Stocks Lower in October - OIS Index - Healthegy

At last month’s OIS@AAO, we introduced the OIS Index. To learn more about its origins and intent, listen to this OIS Podcast interview.

By Michael Lachman, EyeQ Research

The OIS Index is a composite of ophthalmic growth stocks, consisting of 29 small- and mid-cap companies that derive at least half of their value from ophthalmic products and technology. The index was launched on October 1 with an initial base value of 1,000.

Over the first month since launch, the OIS Index was down 12.4% to 875.7, a slightly larger decline compared with the NASDAQ Biotechnology Index over the same period (down 11.4%). The US Medical Device Index also declined (down 7.2%), and all of these health care technology indices underperformed the broader US stock market in October (Russell 3000 Index down 2.3%).

The largest positive contributor to OIS Index valuation during October was Clearside Biomedical (CLSD, up 24.7%, +12.8 points in the OIS Index). The stock performed well between mid-September and mid-October, in advance of clinical trial results reported at AAO from two Phase II trials. Another positive contributor was Ohr Pharmaceutical (OHRP, up 11.3%, +1.5 points).

The largest negative contributor to the OIS Index in October was Ophthotech (OPHT, down 22.3%, –17.9 points in the OIS Index). The stock declined steadily through the month, leading up to the October 31 publication of Phase IIb results of Fovista in combination with Lucentis for wet age-related macular degeneration (AMD). Other negative contributors were Spark Therapeutics (ONCE, down 21.7%, –17.3 points) and Omeros (OMER, down26.5%, –15.9 points).

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

How Omega Ophthalmics Hopes to Redefine Use of the Capsular Bag with the Gemini Refractive Capsule

How Omega Ophthalmics Hopes to Redefine Use of the Capsular Bag with the Gemini Refractive Capsule

Glaukos' Bid for Avedro: What's Next

A Closer Look at Glaukos’ Bid for Avedro

OIS@ASRS Reporter's Notebook: Three Things Learned at OIS@ASRS About What Funders Want, Going Global, and AI

OIS@ASRS Reporter’s Notebook: Three Things Learned at OIS@ASRS About What Funders Want, Going Global, and AI

Recent Moves Show How Zeiss Is Positioning Itself for a New Era in Ophthalmology

Recent Moves Show How Zeiss Is Positioning Itself for a New Era in Ophthalmology

National Vision and Eye Health Surveillance System Gears Up for September Launch

National Vision and Eye Health Surveillance System Gears Up for September Launch

OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space

About The Author

Michael Lachman

Michael Lachman is President of EyeQ Research, which provides market research, analytics, and strategic advisory to ophthalmic companies and investors. Previously, he was a healthcare investment research analyst with Hambrecht & Quist, ThinkEquity Partners, and SAC Capital, and worked in business development, marketing, and R&D for Johnson & Johnson and Baxter.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.